Screen the entire global market — including names the crowd has left for dead — by quality, growth, returns and valuation.
Every subsector ranked on valuation, income, returns and leverage, computed from our own company financials with a book-value NAV proxy. Click a subsector for its full report.
We have researched 360 Finance. The verdict, the fair value and the argument behind them are available to Premium members.
A PrimerIQ deep dive is a full research report on the company and everything around it — not a summary of one annual report. It covers:
You get a bear, base and bull case with the assumptions behind each, the price we think it is worth, and the specific things that would break the thesis.
Put a question to the analyst and get an answer grounded in this company's own filings and our research — "what breaks the thesis?", "how much of profit goes to interest?"
Included from Premium →It takes up to 3 hours and covers the filings, the competitors, the news, the wider industry, the economy it sits in, the regulatory backdrop, and a full model and a fair value with sensitivities. It runs in the background — we will let you know when it lands, so you do not need to keep this page open.
Annual financial statements as reported, going back as far as the data allows.
| $m | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E |
|---|
| $m | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E |
|---|
| $m | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E |
|---|
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E |
|---|
Who bought and sold, at what price, and how much of their own holding it was — from SEC Form 4 and UK PDMR notifications, with each insider's last-reported position and disclosed major holders.
This company has been valued on Justified price-to-book, Residual income (excess returns on book), with a year-by-year forecast, the cost of capital built up from the risk-free rate, a bear/base/bull scenario set and a sensitivity grid. The fair value and the scenario range are on the Overview; the workings behind them — every driver, rate and sensitivity — are Premium.
The 6 investable Credit Services industry peers closest in size, largest first. Market caps are shown in USD so the set compares like with like; the multiples are currency-neutral. The median is taken across the PEERS only — it is what this company is being compared to — and per column, over the peers that actually report each measure.
| Company | Mkt cap (USD) | P/E | P/B | ROIC | Op margin | Div yield |
|---|---|---|---|---|---|---|
| Genertec Universal Medical 5UM | $1.2bn | 3.6× | 0.38× | 5.2% | 21.8% | 7.8% |
| Srisawad Power 1979 PCL SAWAD | $1.2bn | 7.3× | 1.0× | 8.0% | 49.1% | 1.8% |
| SUN HUNG KAI SHK | $1.1bn | 5.5× | 0.39× | — | — | 5.8% |
| 360 Finance QFIN | $1.1bn | 2.0× | 0.31× | 24.7% | 34.8% | 11.6% |
| CHANNEL VAS INV OPA | $1.1bn | — | — | — | — | — |
| B2 Impact ASA B2I | $1.1bn | 14.8× | 1.7× | 8.9% | 45.9% | 6.0% |
| Qfin CKR0 | $1.0bn | 1.4× | 0.29× | — | — | 16.8% |
| Peer median | $1.1bn | 5.5× | 0.39× | 8.0% | 45.9% | 6.0% |
A comparable set says what the market is paying for similar businesses today, not what any of them is worth. It is a cross-check on the model above, not a substitute for it.
A full deep-dive (business, moat, risks, valuation and scenarios) hasn't been generated for this company yet.
Source documents straight from the database — click to read the raw filing or release — beside the issuer's own releases and dated events, newest first. Our read on what matters lives in Recent developments.
Upcoming and recent investor events — results, AGM, dividend and ex-dividend dates — from the company's own investor calendar.
Every place this issuer trades — the home listing, foreign cross-listings and depositary receipts (ADR/CDR/BDR), plus any separate share classes. The screener shows one canonical line per company; the rest live here.
| Listing | Exchange | Ticker | Currency | Price | Type |
|---|
Interactive price chart with the common technical-analysis overlays and indicators — moving averages, Bollinger Bands, volume, RSI and MACD — plus an at-a-glance momentum summary. Use the chart's own toolbar to add or remove studies, change timeframe, or search a different listing.
A note on method: PrimerIQ's research is built bottom-up from the filings — what a business earns and what it's worth. The charts below read price history, not the business; we include them because many investors want them, not because they drive our valuation. Treat them as one lens among several.
Relative strength percentile: 35 vs market, 32 vs industry. Momentum rank is a 0–100 percentile across 36,468 companies — one lens, not a valuation signal.
Charts and technical data by TradingView. Not investment advice.
The webcast audio itself, transcribed in full, with the structural signals the transcript text alone loses — how scripted rather than spontaneous the language is, where management hesitated longest, and which answers were most hedged.
Included from Premium →Select a filing on the left to read it here.
Select a filing to view its raw text.